



Vaccines and Global Health: The Week in Review
25 January 2025 :: Issue 783
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

:: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

Gavi and partners pioneer new approach to deliver critical vaccinations in humanitarian contexts

- In partnership with the International Rescue Committee (IRC) and others, the Gavi-funded Humanitarian Partnerships (ZIP) is breaking new ground in how immunisation services reach communities affected by insecurity, conflict or crisis
- **The programme, which launched in 2022, spans across 11 African countries in the Sahel and Horn of Africa.**
- “Gavi is unwavering in its commitment to ensuring every child, no matter their circumstances, has access to life-saving vaccines. Our partnership with humanitarian actors is a testament to this commitment, enabling us to reach communities affected by instability, insecurity, conflict and crisis,” said Thabani Maphosa, Chief Country Delivery Officer at Gavi

Geneva, 21 January 2025 – **A new report, *Gavi’s Humanitarian Partnerships: achievements and learning, 2022–2024*, shows how Gavi and humanitarian partners are bridging immunisation gaps** to reach children and infants living in crisis-affected settings across 11 countries in Africa, paving the way for solutions that address the needs of some of the most vulnerable populations – while improving health security around the world.

According to the report, integrating humanitarian and immunisation services through Gavi’s Humanitarian Partnerships (ZIP) has **enabled the delivery of life-saving vaccines to children in hard-to-reach and conflict-afflicted communities, without compromising quality**. By addressing and overcoming various equity barriers that have long hindered global vaccination progress, Gavi and partners have helped protect hundreds of thousands from life-threatening and highly contagious diseases like measles.

With new access to vaccinate children in these communities, the partnership has also pioneered new ways of working for the Vaccine Alliance, partnering with nongovernmental humanitarian organisations for the first time. **ZIP has additionally delivered routine childhood vaccines to children up aged up to five years who previously missed out – an unprecedented achievement in humanitarian contexts...**

...Launched as a pilot in 2022, Gavi’s Humanitarian Partnerships (ZIP) were designed to address inequities in vaccine access, prioritising communities that were previously left behind. **Working in partnership with the IRC, World Vision and consortia of local civil society organisations, the initiative has proven that effective immunisation programmes can succeed in even the most complex humanitarian contexts**, including semi-autonomous or separatist areas, non-state armed group locations, refugee camps and among marginalised populations.

.....
.....

IHR Joint External Evaluation (JEE) – USA

Joint external evaluation of the International Health Regulations (2005) core capacities of the USA

14 January 2025 | Country report

Overview

The Joint External Evaluation (JEE) team would like to express its appreciation to the United States of America for volunteering to undertake a second JEE using the third edition of the JEE tool. This revised edition of the tool incorporates relevant lessons of the COVID-19 pandemic and other public health emergencies.

The JEE team sincerely appreciates the United States' efforts to meet the requirements of the JEE process, and the warm hospitality that was offered to the JEE team. All countries that make the effort to undergo the JEE process should be commended for the transparency they have shown in service of strengthening global health security.

Findings from the Joint External Evaluation

During the JEE mission, which took place in Washington, DC and Atlanta, Georgia from 18 to 25 September 2024, the **United States' capacities in 19 technical areas were evaluated through a peer-to-peer, consultative process**. This process brought together a multisectoral group of national subject matter experts and the multinational, multidisciplinary expert JEE team for a week of discussion, interaction and selected site visits.

After a week of collaborative talks this process led to consensus on scores, as well as JEE recommendations for priority actions across the 19 technical areas.

The evaluation also generated eight wider, overarching recommendations that, if implemented, will consolidate the United States' progress and remove bottlenecks that might impede implementation of the agreed priority actions. These recommendations, outlined below, address cross-cutting challenges affecting the capacities of the United States across many of the different technical areas that were explored in greater depth in the JEE process.

Overarching recommendations of the JEE

1. **Structures:** continue to improve alignment and harmonization of political, legal, and technical frameworks across all regions and territories.
2. **Extend preparedness** to the level of state, local, tribal and territorial (SLTT) jurisdictions, ensuring that any capacity gaps in SLTTs are addressed so that preparedness, prevention, detection and response are rooted at local level.
3. **Workforce:** ensure close monitoring of the US\$ 7 billion American Rescue Plan workforce investments and other initiatives to strengthen the future public health workforce, addressing declining trends in workforce numbers and the high proportion of staff considering leaving the public sector.
4. **Funding:** maintain investment in preparedness through existing agencies and programmes and consider reviewing the cost effectiveness of how funds are currently used, with particular focus on addressing fragmentation and duplication.
5. **Trust:** strengthen community engagement to improve the impact of emergency responses, with focus on building trust – ensuring the inclusion of communities that are harder to reach, or which have diverse needs.
6. **Strengthen trust in data, services, and systems.**
7. **Equity:** continue measures to ensure health security for all the population of the United States, addressing existing inequities and working to expand coverage of essential health care through federal initiatives, more and better partnerships, and improved health literacy and research.
8. **Solidarity: continue the United States' admirable contributions to global health security and solidarity, maintaining the willingness to share the benefits of its high capacity through deployment of staff to other parts of the world, training, capacity building, and sharing of knowledge and best practices.**

.....
.....

WHO Membership – USA

WITHDRAWING THE UNITED STATES FROM THE WORLD HEALTH ORGANIZATION

Presidential Actions

EXECUTIVE ORDER January 20, 2025

[Excerpt; Editor's text bolding]

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered:

Section 1. Purpose. The United States noticed its withdrawal from the World Health Organization (WHO) in 2020 due to the organization's mishandling of the COVID-19 pandemic that arose out of Wuhan, China, and other global health crises, its failure to adopt urgently needed reforms, and its inability to demonstrate independence from the inappropriate political influence of WHO member states. In addition, the WHO continues to demand unfairly onerous payments from the United States, far out of proportion with other countries' assessed payments. China, with a population of 1.4 billion, has 300 percent of the population of the United States, yet contributes nearly 90 percent less to the WHO.

Sec. 2. Actions.

(a) The United States intends to withdraw from the WHO. The Presidential Letter to the Secretary-General of the United Nations signed on January 20, 2021, that retracted the United States' July 6, 2020, notification of withdrawal is revoked.

(b) Executive Order 13987 of January 25, 2021 (Organizing and Mobilizing the United States Government to Provide a Unified and Effective Response to Combat COVID-19 and to Provide United States Leadership on Global Health and Security), is revoked.

(c) The Assistant to the President for National Security Affairs shall establish directorates and coordinating mechanisms within the National Security Council apparatus as he deems necessary and appropriate to safeguard public health and fortify biosecurity.

(d) The Secretary of State and the Director of the Office of Management and Budget shall take appropriate measures, with all practicable speed, to:

(i) pause the future transfer of any United States Government funds, support, or resources to the WHO;

(ii) recall and reassign United States Government personnel or contractors working in any capacity with the WHO; and

(iii) identify credible and transparent United States and international partners to assume necessary activities previously undertaken by the WHO.

(e) The Director of the White House Office of Pandemic Preparedness and Response Policy shall **review, rescind, and replace the 2024 U.S. Global Health Security Strategy as soon as practicable.**

Sec. 3. Notification. The Secretary of State shall immediately inform the Secretary-General of the United Nations, any other applicable depositary, and the leadership of the WHO of the withdrawal.

Sec. 4. Global System Negotiations. **While withdrawal is in progress, the Secretary of State will cease negotiations on the WHO Pandemic Agreement and the amendments to the International Health Regulations, and actions taken to effectuate such agreement and amendments will have no binding force on the United States...**

THE WHITE HOUSE, January 20, 2025.

WHO comments on United States' announcement of intent to withdraw

21 January 2025

Statement

The World Health Organization regrets the announcement that the United States of America intends to withdraw from the Organization.

WHO plays a crucial role in protecting the health and security of the world's people, including Americans, by addressing the root causes of disease, building stronger health systems, and detecting, preventing and responding to health emergencies, including disease outbreaks, often in dangerous places where others cannot go.

The United States was a founding member of WHO in 1948 and has participated in shaping and governing WHO's work ever since, alongside 193 other Member States, including through its active participation in the World Health Assembly and Executive Board. For over seven decades, WHO and the USA have saved countless lives and protected Americans and all people from health threats. Together, we ended smallpox, and together we have brought polio to the brink of eradication. American institutions have contributed to and benefited from membership in WHO.

With the participation of the United States and other Member States, WHO has over the past 7 years implemented the largest set of reforms in its history, to transform our accountability, cost-effectiveness, and impact in countries. This work continues.

We hope the United States will reconsider and we look forward to engaging in constructive dialogue to maintain the partnership between the USA and WHO, for the benefit of the health and well-being of millions of people around the globe.

Statement from Gates Foundation CEO Mark Suzman: On the U.S. Withdrawal From the World Health Organization

Press release Jan 21, 2025

Providing access to essential health care for the world's most vulnerable people not only reflects America's core values, it strengthens global stability, security, and prosperity. The World Health Organization plays a vital role in combatting health threats that impact everyone, including Americans, by preventing the spread of deadly diseases, coordinating responses to health emergencies, and implementing global health initiatives—saving millions of lives each year. We believe engaged U.S. leadership is essential to helping build a more effective and efficient global health system with the WHO playing a central role. As we look to the future, we will continue to make the case that instead of retreating, leaders in the United States should prioritize strengthening WHO's capacity to address global health challenges, ensuring that U.S. investments continue to build a healthier, safer future for all.

PATH statement on US withdrawal from WHO

January 21, 2025 by PATH

The World Health Organization (WHO) plays a critical role in keeping Americans and the world safe from deadly diseases and health threats. We urge the Trump Administration to reconsider its position on US withdrawal from WHO. At a time when we are facing multiple health crises—including mpox, cholera, and antimicrobial resistance (AMR)—a strong and effective WHO is more important than ever.

PATH has partnered with WHO for nearly five decades, witnessing firsthand the organization's lifesaving impact. From strengthening disease surveillance and establishing early warning systems to improving capacity for mRNA vaccine manufacturing that will accelerate outbreak response, supporting the rollout of the world's first malaria vaccine, and helping eliminate meningitis outbreaks in Africa, WHO's lifesaving efforts advance US health and development goals.

The US holds a pivotal leadership role within the WHO, helping shape its priorities, promoting reforms, and ensuring alignment with American interests. As just one example, the WHO's "Transforming for Impact" program, launched during Trump's first Administration, is one of many initiatives strengthening WHO's fiscal management, operational efficiency, and procurement processes. In its most recent investment round, the WHO secured pledges from 70 donors, with more than half making voluntary contributions for the first time—a testament to the growing global commitment to strengthening health security worldwide.

A US withdrawal from WHO will create a leadership vacuum that will increase local and global vulnerabilities to infectious disease and emerging health threats. By maintaining US membership in WHO, the US can protect its interests and harness its influence to:

- Continue to broaden WHO's donor base, reducing over-reliance on US funding.
- Strengthen transparency and operational performance.
- Support improvements to regulatory mechanisms like WHO's global priority review process, enabling timely access to lifesaving products worldwide.
- Enhance the world's preparedness for future pandemics.

With continued US leadership, WHO can better protect health at home and abroad, advancing shared US priorities and ensuring a safer, healthier world for all.

.....

[The World Medical Association Calls for Sustained Global Support of the World Health Organization](#)

23.01.2025

The World Medical Association (WMA) strongly urges maintaining robust support for the World Health Organization, emphasizing its critical importance as a functional global health agency. Though it certainly needs strategic improvements, the WHO represents the primary international mechanism for coordinating global health initiatives and addressing worldwide health challenges.

"The WMA urges global leadership, particularly major economic powers, to demonstrate unwavering commitment to the WHO through sustained financial support and constructive engagement. The WHO remains our most essential instrument for addressing global health challenges. While reform is imperative, withdrawal or diminished support would critically compromise international health security.", stated Dr. Ashok Philip, WMA President.

The WMA specifically urges states to remain committed to the WHO, contribute to constructive dialogue about organizational improvements, and ensure consistent and fair funding for critical global health programs. "The announced exit of the United States from WHO will not only leave a huge budget hole, it will more importantly produce a significant political vacuum, which may have far more negative impact than just the decline in funds. Instead of disengagement, our Nations should empower

the WHO to serve as the most comprehensive mechanism for international health coordination, disease prevention, and emergency response.”, Dr Philip concluded.

.....
.....

Cholera

Multi-country outbreak of cholera, External situation report #22 - 24 January 2025

24 January 2025

Overview

Data as of 29 December 2024

- **In December 2024 (epidemiological weeks 49 to 52), a total of 45 986 new cholera cases were reported from 21 countries**, territories, areas (hereafter countries) across three WHO regions, representing a 22% decrease from the previous month. The Eastern Mediterranean Region registered the highest number of cases, followed by the African Region and the South-East Asia Region. Additionally, 457 cholera-related deaths were reported globally, highlighting an 8% increase compared with November.
- The number of cases and deaths in December 2024 are 21% and 5% lower, respectively, than those reported in December 2023.
- **Conflict, mass displacement, disasters from natural hazards, and climate change have intensified outbreaks, particularly in rural and flood-affected areas**, where poor infrastructure and limited healthcare access delay treatment. These cross-border factors have made cholera outbreaks increasingly complex and harder to control.
- Since the last report, new cholera outbreaks have been reported in Zambia, though the total number of affected countries in 2024 remains unchanged at 33.
- **From 1 January to 29 December 2024, a cumulative total of 804 721 cholera cases and 5805 deaths were reported from 33 countries across five WHO regions.** The Eastern Mediterranean Region recorded the highest numbers, followed by the African Region, the South-East Asia Region, the Region of the Americas, and the European Region. No outbreaks were reported in the Western Pacific Region during this period.
- **In December, Oral Cholera Vaccines (OCV) production remained high at 5.5 million doses, thanks to a simplified formulation and production process introduced and prequalified in 2024.[1]** This new formulation and process allowed the average stockpile to rise to 5.9 million doses in December compared to 3.5 million and 0.6 million, respectively in November and October – exceeding the five million doses needed for emergency stockpile at all times for effective outbreak response. However, the increased production has yet to meet growing global demand, as demand continues to exceed supply, which continues to hinder efforts to control cholera outbreaks and respond rapidly to the disease’s spread.

1 WHO prequalifies new oral simplified vaccine for cholera: Available at:

<https://www.who.int/news/item/18-04-2024-who-prequalifies-new-oral-simplified-vaccine-for-cholera#>

Operational updates

...Vaccination

- **The global OCV stockpile averaged 5.9 million doses in December, exceeding the target of 5 million doses that should be available at all times for outbreak response.**
- Thirty-three new emergency requests were circulated in 2024 from Bangladesh, Comoros, Ethiopia (3), Ghana (3), Kenya, Malawi, Mozambique (2), Myanmar (3), Niger (2), Nigeria, Somalia, South Sudan (5), Sudan (6), Yemen, Zambia, and Zimbabwe, collectively seeking 52 million doses (for single round campaigns). Thirty were approved, two were not approved, and one was cancelled by the International Coordinating Group (ICG) on Vaccine Provision.

- Since the start of 2024, 13 countries (Comoros, Ethiopia (4), Ghana (2), Mozambique (3), Myanmar, Niger, Nigeria, Somalia, South Sudan (3), Sudan (5), Yemen, Zambia (2), and Zimbabwe (2)) have carried out 27 reactive vaccination campaigns in response to cholera outbreaks, targeting a total of 34 million people. Given the ongoing outbreaks and limited vaccine availability, only single-dose vaccination campaigns have been approved and implemented.
- **In December, OCV production remained robust**, reflecting significant efforts by the supplier and partners. This progress follows the introduction and prequalification of a new vaccine formulation and manufacturing process earlier in 2024.
- Despite these efforts, **the mismatch between OCV supply and growing demand is severely constraining the capacity to mount preventive vaccination campaigns**. The current limitations of the global stockpile underscore the urgent need for increased production and more strategic stockpile management to meet both reactive and preventive needs.

.....

mPox – PHEIC

No new digest content identified.

.....

Polio – PHEIC

Polio this week – 22 January 2025

Headlines

No new headlines identified.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Afghanistan: 13 WPV1-positive environmental samples
- Pakistan: three WPV1 cases and four WPV1-positive environmental samples
- Algeria: one cVDPV2-positive environmental sample
- DR Congo: one cVDPV1 case
- **Occupied Palestinian territory: three cVDPV2-positive environmental samples**
- South Sudan: one cVDPV2-positive environmental sample

.....

Public Consultations/Call for Inputs/Call for Papers

E6(R3) Good Clinical Practice: Annex 2; International Council for Harmonisation; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 12/30/2024 **Comment period ends 02/28/2025**
SUMMARY:

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "E6(R3) Good Clinical Practice: Annex 2." The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance is the second annex to "E6(R3) Good Clinical Practice" published June of 2023. This annex provides additional considerations for the application of good clinical practices to a variety of trial designs and data sources. Specifically, this draft guidance discusses trials with decentralized and pragmatic elements and real-world data sources. This draft

guidance highlights the importance of quality by design and focusing efforts and resources on critical aspects of the trials that might impact the safety of participants and the reliability of results. The draft guidance is intended to encourage innovation in trial design and provides flexible, modern, and clear good clinical practices for conducting trials, while avoiding unnecessary complexities.

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

WHO & Regional Offices [to 25 Jan 2025]

<https://www.who.int/news>

Selected News/Announcements/Statements

23 January 2025 *News release*

[**Georgia certified malaria-free by WHO**](#)

21 January 2025 *Statement*

[**WHO comments on United States' announcement of intent to withdraw**](#)

19 January 2025 *News release*

[**The ceasefire in Gaza brings hope, but immense challenges lie ahead to restore the health system**](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 24 January 2025

[**WHO ramps up support for Tanzania's Marburg outbreak response**](#)

:: 22 January 2025

[**South Sudan steps up vaccination, response measures to curb cholera**](#)

WHO Region of the Americas PAHO

:: 24 Jan 2025

[**PAHO calls for intensified efforts to address Leprosy and other Neglected Tropical Diseases**](#)

Washington, D.C., January 24, 2025 (PAHO) – On the occasion of World Neglected Tropical Diseases (NTD) Day, the Pan American Health Organization (PAHO) has called for increased efforts to eliminate these diseases, which affect more than 50 million people in the Region of the Americas. Leprosy, dengue, Chagas disease, leishmaniasis, rabies, scabies...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

[:: **Statement from the WHO Regional Office for Europe on the release of hostages from Gaza during Phase 1 of the ceasefire between Israel and Hamas**](#)

19 January 2025

WHO Eastern Mediterranean Region EMRO

[:: **WHO-supported health facility in Ghor province makes childbirth safer for mothers**](#)

21 January 2025

[:: **How WHO is supporting cholera outbreak response in Sudan**](#)

19 January 2025

[:: **Cholera vaccination drive completes in Al-Hol camp, tackling outbreak in record time**](#)

19 January 2025

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

24 January 2025

[**Multi-country outbreak of cholera, External situation report #22 - 24 January 2025**](#)

23 January 2025

[**Sudan conflict – Situation in refugee-hosting countries, Multi-country External Situation Report #8, covering the reporting period December 2024**](#)

Highlights

The ongoing conflict in Sudan continues to drive a large influx of refugees into surrounding countries.

- Eastern Chad continues to report chickenpox and hepatitis E. In addition, there is an increase in diarrhoea.
- **There is an ongoing cholera outbreak in South Sudan**, and more than 13 700 suspected cholera cases have been reported. There is a link with the continued influx of returnees and refugees crossing the border from Sudan, making it difficult to ensure adequate water and sanitation conditions and healthcare services. Malaria accounted for the largest number of cases compared to other disease conditions in Renk County.
- In Egypt, WHO provided extensive support to the Ministry of Health and Population and other partners, covering health financing, procurement of medical supplies, healthcare provision and water, sanitation and hygiene (WASH).
- In Libya, WHO has continued activities in Emergency Medical Teams (EMTs) and mental health and psychosocial support (MHPSS), in addition to strengthening laboratory capacity.
- **There are continued outbreaks of malaria in Ethiopia. and hepatitis E in Central African Republic.** WHO provided technical support for outbreak response activities.
- Security concerns persist and ongoing hostilities between armed groups threaten the safety of civilians in Sudan and neighboring countries, causing further displacement and adding significant challenges to infectious disease control and the delivery of medical countermeasures and humanitarian aid.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[20 January 2025 | Chapare haemorrhagic fever- the Plurinational State of Bolivia](#)

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 100, Nos. 04, pp. 21–32 24 January 2025

PDF: <https://iris.who.int/bitstream/handle/10665/380279/WER10004-21-32.pdf>

:: Elimination of visceral leishmaniasis as a public health problem in Kenya – progress and challenges

.....

New WHO Publications

<https://www.who.int/publications>

Selected

24 January 2025

[WHO technical consultation on evidence-informed decision-making for prevention of and response to sexual...](#)

22 January 2025

[Practical approaches and case-based models for reaching men and boys with integrated HIV services](#)

22 January 2025

[Human rabies post-exposure prophylaxis workshop on supporting countries to build a case for investment:...](#)

.....

.....

USA – HHS, FDA, CDC

Editor's Note:

A *Washington Post* article on January 21, 2025 by Lena H. Sun, Dan Diamond and Rachel Roubein reported that "The Trump administration has instructed federal health agencies to pause all external communications, such as health advisories, weekly scientific reports, updates to websites and social media posts, according to nearly a dozen current and former officials and other people familiar with the matter. The instructions were delivered Tuesday to staff at agencies inside the Department of Health and Human Services, including the Food and Drug Administration, the Centers for Disease Control and Prevention and the National Institutes of Health, one day after the new administration took office, according to the people with knowledge, who spoke on the condition of anonymity to describe private conversations..."

We did not identify any White House or HHS advisory related to this reported "pause."

HHS

News

Last news release 17 Jan 2025.

FDA

Press Announcements

Last announcement 17 Jan 2025.

FDA VRBPAC

Advisory Committee Calendar

No new VRBPAC calendar dates identified.

CDC/ACIP [U.S.] [to 25 Jan 2025]

<http://www.cdc.gov/media/index.html>

Latest News

Last news release 10 Jan 2025.

ACIP Meetings

Next ACIP Meeting

February 26-27, 2025

MMWR Weekly

<https://www.cdc.gov/mmwr/index2024.html>

The January 16th MMWR [below] which we carried in our last edition no longer appears on the MMWR webpage. We note the two ACIP recommended immunization schedules that comprise this edition. The PDF link below is still active.

January 16, 2025 / No. 2

[PDF of this issue](#)

- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2025](#)
- [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2025](#)

.....

.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

No new digest content identified.

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

[Reporting protocol for zoonotic influenza virus](#)

21 Jan 2025

This reporting protocol describes data collection for human cases of zoonotic influenza viruses, with the aim to support assessment of key indicators and trends over time and inform situational risk assessments.

.....

.....

Africa CDC [to 25 Jan 2025]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Press Releases

Tanzania Declares Marburg Outbreak: Africa CDC Mobilizes Immediate Response

20 January 2025

.....

China CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 25 Jan 2025]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 25 Jan 2025]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-01-24 / No. 4 INFECTIOUS DISEASE ISSUE

[PDF of this issue](#)

- [Vital Surveillances: Respiratory Pathogen Profiles of Patients — Beijing Municipality, China, November 2023–April 2024](#)
- [Vital Surveillances: Characterization of Aeromonas Strains Isolated from Adult Patients with Diarrhea and Aquatic Environments — Beijing Municipality, China, 2016–2022](#)
- [Preplanned Studies: Epidemiological and Spatiotemporal Clustering Analysis of Human Brucellosis — China, 2019–2023](#)
- [Preplanned Studies: Multicenter Study on the Prevalence of Human Respiratory Syncytial Virus Coinfection and Disease Burden Among Hospitalized Children Aged 5 Years and Younger — 5 Prefecture-level Cities, Zhejiang Province, China, 2018–2023](#)
- [Methods and Applications: Automatic Warning Practice of Multi-Source Surveillance and Multi-Point Trigger for Infectious Diseases — Yuhang District, Hangzhou City, Zhejiang Province, China, January–April 2024](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, November 2024*](#)

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Organization Announcements

Paul G. Allen Frontiers Group [to 25 Jan 2025]

<https://alleninstitute.org/news-press/>

News

[New research reveals how location influences how our immune system fights disease](#)

01.22.2025

Findings could pave the way for improved immunotherapies and vaccines.

Annual Report News

[2024 Impact Report](#)

01.20.2025

A year of breakthroughs and collaboration at the Allen Institute.

BMGF - Gates Foundation [to 25 Jan 2025]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

Press release Jan 24, 2025

[Statement from CEO Mark Suzman: On the Reinstatement of the Mexico City Policy](#)

Reinstating the Mexico City Policy puts access to critical services for millions of people at risk—especially access to health services for women and girls. For many women in the world's poorest places, access to comprehensive reproductive health care isn't just about family planning—it's a lifeline that helps keep themselves and their children alive. When women decide whether and when to have children, it saves lives, improves health outcomes, expands education, and creates prosperity—no matter which country in the world you're talking about. We hope America's leaders focus on improving women's health and empowering organizations to deliver essential care—not creating barriers that endanger the lives of women worldwide.

Press release Jan 21, 2025

[Statement from CEO Mark Suzman: On the U.S. Withdrawal From the World Health Organization](#)

Bill & Melinda Gates Medical Research Institute [to 25 Jan 2025]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 25 Jan 2025]

<https://carb-x.org/>

News

01.23.2025 |

[CARB-X funds Immunartes to develop Staphylococcus aureus preventative](#)

CARB-X will award Immunartes US\$729k to develop a monoclonal antibody to prevent infections caused by Staphylococcus aureus.

Chan Zuckerberg Initiative [to 25 Jan 2025]

<https://chan Zuckerberg.com/newsroom/>
Newsroom
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 25 Jan 2025]

<http://cepi.net/>
CEPI News
News

[Afrigen to develop human mRNA Rift Valley fever vaccine](#)

CEPI funding will advance the vaccine candidate through preclinical development and Phase I trials.
19 Jan 2025

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 25 Jan 2025]

<https://cioms.ch/>
News; Publications; Events
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 25 Jan 2025]

<https://www.darpa.mil/news>
News
No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [to 25 Jan 2025]

<https://dndi.org/press/press-releases/>
Press Releases
No new digest content identified.

Duke Global Health Innovation Center [to 25 Jan 2025]

<https://dukeghic.org/>
News

[Issue 6: 23 January 2025 | Mpox: Transparency and Accountability for the Global Response](#)

January 23, 2025

EDCTP [to 25 Jan 2025]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

21 January 2025

[New tablet shows promise for the control and elimination of intestinal worms](#)

Emory Vaccine Center [to 25 Jan 2025]

<http://www.vaccines.emory.edu/>
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 25 Jan 2025]

<http://www.euvaccine.eu/>
Latest News, Events
No new digest content identified.

Fondation Merieux [to 25 Jan 2025]

<http://www.fondation-merieux.org/>
News, Events
No new digest content identified.

Gavi [to 25 Jan 2025]

<https://www.gavi.org/>
Press Releases

21 January 2025

Gavi and partners pioneer new approach to deliver critical vaccinations in humanitarian contexts

- In partnership with the International Rescue Committee (IRC) and others, the Gavi-funded Humanitarian Partnerships (ZIP) is breaking new ground in how immunisation services reach communities affected by insecurity, conflict or crisis
- The programme, which launched in 2022, spans across 11 African countries in the Sahel and Horn of Africa.
- "Gavi is unwavering in its commitment to ensuring every child, no matter their circumstances, has access to life-saving vaccines. Our partnership with humanitarian actors is a testament to this commitment, enabling us to reach communities affected by instability, insecurity, conflict and crisis," said Thabani Maphosa, Chief Country Delivery Officer at Gavi

GE2P2 Global Foundation [to 25 Jan 2025]

www.ge2p2.org
News/Analysis/Publications-Digests/Statements
:: [Vaccines and Global Health: The Week in Review](#) - Current edition
:: [Informed Consent: A Monthly Review – January 2025](#)
:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 14 Jan 2025](#)

GHIT Fund [to 25 Jan 2025]

<https://www.ghitfund.org/newsroom/press>
Press Releases
No new digest content identified.

Global Fund [to 25 Jan 2025]

<https://www.theglobalfund.org/en/news/>
News Releases
21 January 2025

Global Fund Unveils Pioneering Climate and Health Fund to Accelerate Global Action

The new fund targets the world's most climate-vulnerable nations, delivering urgent support on adaptation and strengthening health systems to safeguard millions from the intensifying impacts of climate change.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 25 Jan 2025]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 25 Jan 2025]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 25 Jan 2025]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 25 Jan 2025]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 25 Jan 2025]

<https://www.iavi.org/>

Press Releases

No new digest content identified.

INSERM [to 25 Jan 2025]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

23 January 2025

ICMRA PQKMS Collaborative Assessment Summary Report

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 25 Jan 2025]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

24 January 2025

The ICH E6(R3) Introductory Training Presentation is now available on the ICH website

Following the adoption of the E6(R3) Guideline on 6 January 2025, a Step 4 Introductory Training Presentation has been developed by the E6(R3) Expert Working Group.

ICRC [to 25 Jan 2025]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

Article 24-01-2025

Debunking harmful narratives about our work in Israel and the occupied Palestinian territory

With the escalation of violence in Israel, and the occupied Palestinian territory of Gaza and West Bank, including East Jerusalem, there has been a proliferation of dehumanizing language and of false and misleading information about the ICRC and our work in the current conflict. In the face of these real-world consequences, for both people and humanitarian actors, we want to clearly address the main harmful narratives against the ICRC and our staff.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 25 Jan 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

Institut Pasteur [to 25 Jan 2025]

<https://www.pasteur.fr/en/press-area>

Press Documents

Institut Pasteur decides to leave X

Press release 2025.01.16

The Institut Pasteur, a research organization which for more than 130 years has been committed to tackling infectious diseases, sharing knowledge and defending science, has decided to leave X because of several serious abuses observed on the platform since its takeover by Elon Musk. We are suspending our day-to-day activities on the platform immediately and will encourage our subscribers to follow us on other platforms, especially Bluesky, which we recently joined. We will leave X officially in the coming weeks once we have completed this process.

ISC / International Science Council [to 25 Jan 2025]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 25 Jan 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 25 Jan 2025]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 25 Jan 2025]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 25 Jan 2025]

<http://www.msf.org/>

Latest [Selected Announcements]

War and conflict

[**DRC: 3 questions on the intensification of the armed conflict in North and South Kivu**](#)

Project Update 25 Jan 2025

Gaza-Israel war

[**MSF mourns the killing of our ninth colleague in Gaza**](#)

Statement 24 Jan 2025

Mexico

[**MSF highlights increased risks for migrants following closure of the US asylum process**](#)

Press Release 23 Jan 2025

National Academy of Medicine - USA [to 25 Jan 2025]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 25 Jan 2025]

<https://www.nationalacademies.org/newsroom>

News

Gregory H. Symmes Named NAS Chief Operating Officer, NRC Executive Officer

Gregory H. Symmes has been named the chief operating officer of the National Academy of Sciences and executive officer of the National Research Council. The Research Council is the operating arm of the NAS, and in partnership with the National Academy of Engineering and National Academy of Medicine, informs public discourse and policymaking with evidence-based advice.

2025-01-22 *News Release*

National Vaccine Program Office - U.S. HHS [to 25 Jan 2025]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 25 Jan 2025]

<http://www.nih.gov/>

News Releases

Last announcement: 17 January 2025

PATH [to 25 Jan 2025]

<https://www.path.org/media-center/>

Newsroom

PATH statement on US withdrawal from WHO

January 21, 2025 by PATH

Sabin Vaccine Institute [to 25 Jan 2025]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 25 Jan 2025]

<http://www.unaids.org/en>

News, Stories, Updates

Press statement

UNAIDS encourages President Donald J. Trump to continue the strong leadership of the United States of America in the global AIDS response

GENEVA, 22 January 2025

UNAIDS calls on leaders at Davos to commit to rapid global access to revolutionary new long-acting HIV medicines

UNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicines

DAVOS/GENEVA, 21 January 2025

UNICEF [to 25 Jan 2025]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Press release 23 January 2025

Nearly a quarter of a billion children's schooling was disrupted by climate crises in 2024 – UNICEF

NEW YORK, 24 January 2025 – At least 242 million students in 85 countries had their schooling disrupted by extreme climate events in 2024, including heatwaves, tropical cyclones, storms, floods, and droughts, exacerbating an existing learning crisis, according to a new UNICEF analysis released today. For the first...

Unitaid [to 25 Jan 2025]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 25 Jan 2025]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 25 Jan 2025]

<https://www.vaccineacceptance.org/>

No new digest content identified.

Vaccine Confidence Project [to 25 Jan 2025]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 25 Jan 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update Newsletter January 2025

Wellcome Trust [to 25 Jan 2025]

<https://wellcome.org/news/all>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 25 Jan 2025]

<https://www.wistar.org/news/press-releases>

Press Releases

January 20, 2025

Scientists at The Wistar Institute and Stanford University Report Encouraging Results on First-in-Human Clinical Trial for an Investigational Drug to Treat Epstein-Barr Virus Cancer

World Bank [to 25 Jan 2025]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 25 Jan 2025]

<https://www.wfpha.org/>

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 25 Jan 2025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

The World Medical Association Calls for Sustained Global Support of the World Health Organization

23.01.2025

WMA commends Israel and Gaza ceasefire and calls for safeguarding of health professionals

23.01.2025

World Organisation for Animal Health [OIE] [to 25 Jan 2025]

<https://www.oie.int/>

Press Releases, Statements

News

WOAH launches The Animal Echo: A global knowledge space for animal health and welfare

Published on 24 January 2025

...The knowledge-sharing space will feature a blend of scientific articles and blogposts written by leading experts in animal, public, and environmental health. These content pieces will offer in-depth insights into various animal health and welfare topics, with a view to enhancing individual and collective understanding of animal health and welfare.

.....

.....

ARM [Alliance for Regenerative Medicine] [to 25 Jan 2025]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 25 Jan 2025]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 25 Jan 2025]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 25 Jan 2025]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 25 Jan 2025]

<https://ifpma.org/>

News, Statements [Selected]

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [to 25 Jan 2025]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 25 Jan 2025]

<http://www.phrma.org/>

Press Releases

[PhRMA Congratulates President Donald Trump on His Inauguration](#)

January 20, 2025

...The pharmaceutical industry is the crown jewel of the American economy, giving American patients more treatment options than anywhere else in the world while supporting millions of high-paying, high-tech jobs around the country. Through innovation we've achieved significant breakthroughs, improved cancer survival rates, cured hepatitis C, **and eradicated devastating diseases like polio and smallpox.** New medicines are transforming our ability to prevent, treat, and cure deadly diseases more effectively, improving patient lives and reducing reliance on the most expensive parts of the health care system...

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases

[AstraZeneca plans C\\$820 million \(US\\$570m\) investment in Canada to advance growing global hub and clinical delivery](#)

PUBLISHED 23 January 2025

700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies

AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, today announced a C\$820 million (US\$570m) investment in Canada, creating more than 700 high-skilled jobs, across all areas of the business. The investment will support the move to a larger, state-of-the-art office facility in the Greater Toronto Area (GTA), Ontario...

Bavarian Nordic

Latest News - No new digest content identified.

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

Biological E

News - No new digest announcements identified

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media - No new digest announcements identified.

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified

Moderna

Press Releases

January 17, 2025

January 24, 2025

Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats

CAMBRIDGE, MA / ACCESS Newswire / January 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years...

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified.

Serum Institute

News & Announcements - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases

SK bioscience and Sanofi Expand Partnership to Target the Domestic Market for RSV and Hepatitis A Prevention Medicines

2025.01.23

-Two companies signed a co-promotion and distribution agreement for Beyfortus® and Avaxim®, expanding the existing agreement.
-Beyfortus®, the only antibody injection for respiratory syncytial virus in Korea, will be administered, targeting all infants during their first RSV season.
-Both companies have a comprehensive collaboration from joint development of pneumonia vaccines to co-marketing strategies.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases

January 22, 2025

[**Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision**](#)

January 20, 2025

[**Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine**](#)

Vector State Research Centre of Virology and Biotechnology

Home - [Website not responding [404 error]]

WestVac Biopharma

Media - Website not responding at inquiry.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 1: E1-65 Jan 2025

<https://journalofethics.ama-assn.org/issue/epidemiology-and-clinical-practice>

Epidemiology and Clinical Practice

Epidemiological research guides health service delivery by informing and transforming clinical guidelines. Reciprocally, how clinicians document information from patients or their loved ones also determines the quality of data epidemiologists use in research. Additionally, some patients' health needs and some communities' health interests are not well captured in observational studies and clinical trials, especially when patient-subjects are lost to follow-up. Attrition of patient-subjects who are uninsured, underinsured, experience transportation or food insecurity, work multiple jobs, or live with complex chronic illnesses or disabilities, for example, creates data capture gaps, which can result in an evidence base that is incomplete and clinical guidelines that are inapt, inequitable, or simply do not apply to a full range of patients. This theme issue investigates these and other complexities of epidemiological data sourcing and the ethics of practice guideline formation.

American Journal of Human Genetics

Jan 02, 2025 Volume 112 Issue 1 p1-198

<https://www.cell.com/ajhg/current>

This month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Loss-of-function variants are typically considered in terms of gene-specific, pathway-dependent effects. An altered protein is produced, affecting the protein-specific pathway or a related phenotype. However, characterizing the gene-specific, pathway-dependent effects alone does not always explain the phenotypic variability observed between individuals with the same mutation or predict disease trajectory. In this issue, Shovlin and Aldred present a parallel paradigm for loss-of-function variants based on proteostasis, the process of maintaining a healthy balance of proteins within a cell.

American Journal of Infection Control

January 2025 Volume 53 Issue 1p1-174

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

January 2025 Volume 68 Issue 1 p1-216

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

January 2025 115(1)

<http://ajph.aphapublications.org/toc/ajph/current>

Displacements to Escape Natural Disasters In The United States

The January issue of *AJPH* focuses on the increasing prevalence of natural disaster-induced displacements within the United States. Featured articles explore disparities in the impact of these displacements and examine their prevalence and correlates. Other articles in this issue address naloxone distribution programs, urban reforestation efforts in Manhattan, the role of health monitoring data in relation to immigration and citizenship, and the use of long-acting reversible contraception.

American Journal of Tropical Medicine and Hygiene

Volume 112 (2025): Issue 1 (Jan 2025)

<https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.112.issue-1.xml>

[Reviewed earlier]

Annals of Internal Medicine

January 2025 Volume 178, Issue 1

<https://www.acpjournals.org/toc/aim/current>

Original Research

Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United States

Jean-François Laprise, PhD, Harrell W. Chesson, PhD, Lauri E. Markowitz, MD, Mélanie Drolet, PhD, and ... et al.

Pages:50–58

Abstract

Background:

In June 2019, the U.S. Advisory Committee on Immunization Practices recommended shared clinical decision making regarding potential human papillomavirus (HPV) vaccination of men and women aged 27 to 45 years ("mid-adults").

Objective:

To examine the incremental cost-effectiveness ratios (ICERs) and number needed to vaccinate (NNV) to prevent 1 HPV-related cancer case of expanding HPV vaccination to subgroups of mid-adults at increased risk for HPV-related diseases in the United States.

Design:

Individual-based transmission dynamic modeling of HPV transmission and associated diseases using HPV-ADVISE (Agent-based Dynamic model for Vaccination and Screening Evaluation).

Data Sources:

Published data.

Target Population:

All U.S. mid-adults and higher-risk subgroups within this population.

Time Horizon:

100 years.

Perspective:

Health care sector.

Intervention:

Expanding 9-valent HPV vaccination to mid-adults and higher-risk subgroups.

Outcome Measures:

ICERs and NNVs.

Results of Base-Case Analysis:

Expanding 9-valent HPV vaccination to all mid-adults, those with more lifetime partners, and those who have just separated was projected to cost an additional \$2 005 000, \$763 000, and \$1 164 000 per quality-adjusted life-year (QALY) gained, respectively. The NNVs to prevent 1 additional HPV-related

cancer case were 7670, 3190, and 5150, respectively, compared with 223 for vaccination of persons aged 9 to 26 years (vs. no vaccination).

Results of Sensitivity Analysis:

The mid-adult strategy with the lowest ICER and NNV was vaccinating infrequently screened mid-adult women who have just separated and have a higher number of lifetime sex partners (ICER, \$86 000 per QALY gained; NNV, 470).

Limitation:

Uncertainty about rate of new sex partners and natural history of HPV among mid-adults.

Conclusion:

Vaccination of mid-adults against HPV is substantially less cost-effective and produces higher NNVs than vaccination of persons younger than 26 years under all scenarios investigated. However, cost-effectiveness and NNV are projected to improve when higher-risk mid-adult subgroups are vaccinated, such as mid-adults with more sex partners and who have recently separated, and women who are underscreened.

Primary Funding Source:

Centers for Disease Control and Prevention.

Artificial Intelligence – An International Journal

Volume 338 January 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/338/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 25 Jan 2025)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 25 Jan 2025)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 25 Jan 2025)

[Association of HIV infection and hospitalization among mpox cases: a systematic review and meta-analysis](#)

Mpox is a viral zoonotic disease that has seen a resurgence in recent years, with outbreaks reaching beyond its traditional endemic zones in Central and West Africa to parts of Europe and North America. The re...

Authors: Muhammed Shabil, Shilpa Gaidhane, R. Roopashree, Mandeep Kaur, Manish Srivastava, Amit Barwal, G. V. Siva Prasad, Pranchal Rajput, Rukshar Syed, Anoop Dev, Danish Kundra, Ambanna Yappalparvi, Prakasini Satapathy, Quazi Syed Zahiruddin, Harish Kumar, Renu Sah...

Citation: BMC Infectious Diseases 2025 25:102

Content type: Systematic Review Published on: 22 January 2025

[Nationwide representative serosurvey of third-grade school children to evaluate the hepatitis B vaccination impact in Kyrgyzstan, 2022](#)

Kyrgyzstan introduced universal hepatitis B childhood vaccination in 1999 to reduce the burden of hepatitis B. In 2016, aligned with the goal of controlling hepatitis B in the WHO European Region, a regional t...

Authors: Michael Brandl, Gulnara Zhumagulova, Gulbara Ishenapysova, Zuridin Nurmatov, Tatiana Enverovna Kuchuk, Nurzhan Zamirbekova, Gulsunai Sattarova, Saikal Temirbekova, Zhanara Bekenova, Martyna Gassowski, Liudmila Mosina, Antons Mozalevskis, Sandra Dudareva and Siddhartha Sankar Datta

Citation: BMC Infectious Diseases 2025 25:100

Content type: Research Published on: 22 January 2025

Effectiveness of HPV vaccination in reducing infection among young Brazilian women

Globally, cervical cancer is an increasing public health issue, and vaccination against HPV has proven to be an effective strategy to reduce this neoplasia. The purpose of this study was to assess the effectiv...

Authors: Ana Carolina da Silva Santos, Nayara Nascimento Toledo Silva, Ismael Dale Cotrim Guerreiro da Silva, Mariângela Carneiro, Wendel Coura-Vital and Angélica Alves Lima

Citation: BMC Infectious Diseases 2025 25:88

Content type: Research Published on: 20 January 2025

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 25 Jan 2025)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 25 Jan 2025)

Knowledge, attitude, and reasons for non-uptake of human papilloma virus vaccination among nursing students

Cervical cancer is a significant health issue, especially in low- and middle-income countries like India, where it ranks fourth among women. The Human papillomavirus (HPV) vaccination, a vital preventive measu...

Authors: Soni Chauhan, Surya Kant Tiwari, Vishal Dubey, Pragya Tripathi, Priyanka Pandey, Anuj Singh and Narendra Pal Singh Choudhary

Citation: BMC Medicine 2025 23:35

Content type: Research Published on: 21 January 2025

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 25 Jan 2025)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 25 Jan 2025)

Burden of pertussis in infants in the Eastern Mediterranean Region and the impact of maternal vaccination: a systematic review

Despite vaccine availability, Pertussis remains a global public health challenge, especially among infants. The Eastern Mediterranean Region (EMR) presents a diverse epidemiological landscape with varying vacc...

Authors: Randa K. Saad, Yousef Khader, Flor M. Munoz, Faris Lami, Ezzeddine Mohsni and Nadine Haddad

Citation: BMC Public Health 2025 25:268

Content type: Systematic Review Published on: 22 January 2025

BMC Research Notes

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 25 Jan 2025)

[No new digest content identified]

BMJ Evidence-Based Medicine

February 2025 - Volume 30 - 1

<https://ebm.bmj.com/content/30/1>

Analysis

[Successes, shortcomings and learning opportunities for evidence-based medicine from the COVID-19 pandemic](#) (30 July, 2024)

Arnav Agarwal, Gordon Guyatt

BMJ Global Health

December 2024 - Volume 9 - 12

<https://gh.bmj.com/content/9/12>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 103, Number 1, January 2025, 1-80

<https://www.who.int/publications/journals/bulletin/>

[In this month's Bulletin](#)

In the editorial section, Katherine Littler et al. (2) call for papers for a special theme issue on the ethics of research into health and climate change.

Gary Humphreys (5–6) reports on initiatives to mitigate unintended consequences of health policies.

Glenda Gray talks to Humphreys (7–8) about her career working on HIV prevention and treatment.

[The ethics of research into health and climate change: call for papers](#)

Katherine Littler, Julian Sheather, Adrienne Sayer

Bull World Health Organ. 2025 Jan 1; 103(1): 2–2A. Published online 2025 Jan 1.

doi: 10.2471/BLT.24.292990 PMID: PMC11704640

... Questions about which research should be given priority are critical, and ethical considerations are underdeveloped. To address this gap, the Bulletin of the World Health Organization will publish a theme issue on the ethics of research into health and climate change. This issue will investigate a range of topics shaping ethically sound climate and health research across a range of methods, populations and disciplines. Papers considered for the theme issue need to provide an advance in the field, and should respond to critical questions such as: what should be investigated and why? What should take priority and according to which criteria? Who or which entities should make decisions regarding the research agenda and by which process(es)? Given that some countries and populations are facing existential threats from climate change – including the risk that their homelands will cease to

exist within decades – what does fair and ethical research into the effects of climate change on their health require? Additionally, the theme issue will cover ethical aspects of climate- and health-related research as they pertain to policy.

The Bulletin welcomes contributions from all stakeholders including public health decision-makers, researchers, civil society and community representatives by 1 June 2025....

Cell

Dec 26, 2024 Volume 187 Issue 26 p7351-7656

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 117, Issue 1 Pages: 1-310 January 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

January 2025 Volume 47 Issue 1 p1-114

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 21 Issue 6, December 2024

<https://journals.sagepub.com/toc/ctja/21/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 25 Jan 2025]

[No new digest content identified]

Contemporary Clinical Trials

Volume 148 January 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/147/suppl/C>

[New issue; No digest content identified]

The CRISPR Journal

Volume 7, Issue 6 / December 2024

<https://www.liebertpub.com/toc/crispr/7/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 12 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2025 - Volume 38 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 25 Jan 2025]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 4 Pages: 263-342 December 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

Development Policy Review

Volume 43, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 49, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>

[Reviewed earlier]

EMBO Reports

Volume 26 Issue 1 10 January 2025

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 1—January 2025

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 49 December 2024

<https://www.sciencedirect.com/journal/epidemics/vol/49/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 6 Pages: 1-35 November–December 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Data monitoring committee insights / Ethics reviews and AI tools

[Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 3 - Fall 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[New issue; No digest content identified]

Ethics, Medicine and Public Health

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 5, October 2024

<https://academic.oup.com/eurpub/issue/34/5>
[Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1
<https://www.tandfonline.com/toc/ierv20/current>
[Reviewed earlier]

Foreign Affairs

January/February 2025
<https://www.foreignaffairs.com/issues/2025/104/1>
Special Section
Will Trump Change the World?

Forum for Development Studies

Volume 51, 2024 - Issue 3
<http://www.tandfonline.com/toc/sfds20/current>
[Reviewed earlier]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>
[Accessed 25 Jan 2025]
[No new digest content identified]

Gene Therapy – Nature

Volume 31 Issue 11-12, November 2024
<https://www.nature.com/gt/volumes/31/issues/11-12>
[Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 1 January 2025
<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/1>
[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>
[Accessed 25 Jan 2025]
[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)
<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>
[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 25 Jan 2025]

[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 25 Jan 2025]

[No new digest content identified]

Health and Human Rights

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

Special Section: Distress Migration and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 3 - July 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 10, December 2024

<https://academic.oup.com/heapol/issue/39/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 25 Jan 2025]

[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 1-2 / January 2024
<https://www.liebertpub.com/toc/hum/36/1-2>
[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024
<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>
Selected Content
[Reviewed earlier]

Immunity

Jan 14, 2025 Volume 58 Issue 1 p1-264
<https://www.cell.com/immunity/current>
[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>
[Accessed 25 Jan 2025]
[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>
[Accessed 25 Jan 2025]
[No new digest content identified]

International Health

Volume 17, Issue 1, January 2025
<https://academic.oup.com/inthealth/issue/17/1>
[Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 2 (Dec 2024)
<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 1 (2025): January 2025
<https://www.ijcmph.com/index.php/ijcmph/issue/view/120>
<https://academic.oup.com/ije/issue/53/6>

[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 6, December 2024

<https://academic.oup.com/ije/issue/53/6>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 4 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>

Table of contents

[Reviewed earlier]

JAMA

January 21, 2025, Vol 333, No. 3, Pages 185-266

<https://jamanetwork.com/journals/jama/currentissue>

Special Communication

AI in Medicine

[FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine](#)

Haider J. Warraich, MD; Troy Tazbaz, BS; Robert M. Califf, MD

JAMA. 2025;333(3):241-247. doi:10.1001/jama.2024.21451

This Special Communication examines advances in the use of artificial intelligence in health care and biomedicine and how regulatory entities like the US Food and Drug Administration must evaluate how artificial intelligence operates within these sectors to develop appropriate regulatory frameworks.

- [Video](#): AI and the FDA
- [Podcast](#): AI and the FDA

Editorial

[The Path to Genomic Screening—Far From Simple, but the Journey Has Begun](#)

Jonathan S. Berg, MD, PhD

JAMA. 2025;333(3):210-212. doi:10.1001/jama.2024.21926

JAMA Health Forum

January 2025, Vol 6, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

January 2025, Vol 179, No. 1, Pages 3-108

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

JB1 Evidence Synthesis

January 2025 - Volume 23 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

January 2025 Volume 76 Issue 1 p1-172

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 81 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 6 December 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-6>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 11 (2024)

<https://www.cmro.in/index.php/jcmro/issue/view/89>

[Reviewed earlier]

Journal of Development Economics

Volume 172 January 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/172/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

December 2024 - Volume 78 - 12

<https://jech.bmj.com/content/78/12>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 4 Pages: 689-873 December 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

Special Issue: 20th Anniversary Forum

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 4, November 2024

<https://muse.jhu.edu/issue/53739>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 6 December 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-6>

Articles

[The Health Status of Undocumented Immigrants from Asian Countries in the United States: A Scoping Review and Recommendations for Future Directions](#)

Sameera S. Nayak, Amanda Cardone, Meghan Dhond

Review Paper Open access 24 August 2024 Pages: 1099 - 1112

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 37, Issue 1 Pages: 1-349 January 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

January 2025 - Volume 51 - 1

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 275 December 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/275/suppl/C>
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

January/February 2025 - Volume 31 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 4, December 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-4>

[Reviewed earlier]

Journal of the Royal Society – Interface

January 2025 Volume 22 Issue 222

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

Journal of Travel Medicine

Volume 31, Issue 8, December 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 98 Number 12 December 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Jan 18, 2025 Volume 405 Number 10474 p173-272, e1-e5

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

[The time for regionalised vaccine manufacturing has arrived](#)

Victor Dzau, Richard Hatchett, Shyam Bishen, Jean Kaseya, Jarbas Barbosa, Farid Fezoua, Frederik Kristensen...RVMC Secretariat

The current approach to global vaccine research and development (R&D), manufacturing, and distribution has greatly expanded routine immunisation, achieving substantial reductions in disease burden over recent decades and helping to save lives and protect economies. Yet this approach has limitations in a world where new pathogens emerge unpredictably and regional needs are increasingly diverging from global priorities.^{[1](#)}

...Regionalised vaccine manufacturing offers a path forward; it can enable equitable access for regions, alignment with regional priorities, and rapid response to outbreaks.² There are evolving challenges that make regionalised vaccine manufacturing necessary for both health emergencies and routine immunisation. The geopolitical landscape has shifted dramatically. Countries and regions are increasingly aware of the vulnerabilities inherent in relying on centralised vaccine production hubs and the political interests that may shape access to scarce resources. Many countries want more self-sufficiency in vaccine manufacturing, given the lessons of the COVID-19 pandemic when there were considerable delays in accessing COVID-19 vaccines due to supply constraints and export bans.³ ...The shift to regionalised vaccine manufacturing is already underway and will not stop. Recent commitments by international and regional bodies, as well as financing and technical support organisations, show regions and stakeholders are not only acknowledging the need for regionalised vaccine manufacturing but are also setting out concrete strategies, policies, and investments that empower regions to sustainably produce the vaccines they need to address regional health priorities (panel).⁵⁻¹¹

The Lancet Child & Adolescent Health

Jan 2025 Volume 9 Number 1 p1-76

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Jan 2025 Volume 7 Number 1 e1-e102

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jan 2025 Volume 13 Number 1 e1-e171

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Jan 2025 Volume 25 Number 1 p1-134, e1-e59

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jan 2025 Volume 10 Number 1 e1-e70

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Jan 2025 Volume 13 Number 1 p1-100, e1-e8

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 12 December 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 1, January 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 4 Pages: 823-1031 December 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Jan 08, 2025 Volume 33 Issue 1 p1-422

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

Nature

Volume 637 Issue 8047, 23 January 2025

<https://www.nature.com/nature/volumes/637/issues/8047>

Article *Open Access* 25 Sept 2024

[H5N1 clade 2.3.4.4b dynamics in experimentally infected calves and cows](#)

Infection studies on highly pathogenic avian influenza virus clade 2.3.4.4b H5N1 on calves and lactating cows indicate that transmission occurs primarily via milk and milking procedures rather than respiratory routes.

Nico Joel Halwe, Konner Cool, Juergen A. Richt

Article *Open Access* 15 Oct 2024

[Dairy cows inoculated with highly pathogenic avian influenza virus H5N1](#)

A study describes the experimental infection of cattle with a highly pathogenic avian influenza H5N1 clade 2.3.4.4b genotype B3.13 strain using an aerosol respiratory route for heifers and an intramammary route for lactating cows.

Amy L. Baker, Bailey Arruda, Patrick J. Gorden

Article *Open Access* 07 Nov 2024

[Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1](#)

A deep mutational scanning approach identifies mutations that allow subvariants of the prevalent JN.1 SARS-CoV-2 strain to evade Omicron-induced neutralizing antibodies, indicating a need for careful monitoring of this lineage in vaccine development.

Fanchong Jian, Jing Wang, Yunlong Cao

Nature Biotechnology

Volume 43 Issue 1, January 2025

<https://www.nature.com/nbt/volumes/43/issues/1>
[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>
(Accessed 25 Jan 2025)
[Reviewed earlier]

Nature Genetics

Volume 57 Issue 1, January 2025
[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 12, December 2024
<https://www.nature.com/nathumbehav/volumes/8/issues/12>
[Reviewed earlier]

Nature Medicine

Volume 30 Issue 12, December 2024
<https://www.nature.com/nm/volumes/30/issues/12>
[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 1, January 2025
<https://www.nature.com/nrd/volumes/24/issues/1>
[Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 1, January 2025
<https://www.nature.com/nrg/volumes/26/issues/1>
[Reviewed earlier]

Nature Reviews Immunology

Volume 25 Issue 1, January 2025
<https://www.nature.com/nri/volumes/25/issues/1>
[New issue; No digest content identified]

New England Journal of Medicine

Volume 392 No. 4 January 23, 2025
<https://www.nejm.org/toc/nejm/medical-journal>
Perspective

[**Ebola and a Decade of Disparities — Forging a Future for Global Health Equity**](#)

C. Spencer

...In the face of current and looming global health threats — including antimicrobial resistance, climate change, and new pandemics — action is urgently needed. Governments and multilateral global health organizations must improve access to existing countermeasures, leverage conditions on public funding and trial agreements to enhance access to new tools, and support local manufacturing in LMICs. The world has the tools to prevent suffering and death in places made vulnerable by a long history of global health inequity. The question is whether we will take the necessary steps to ensure that everyone has access to them.

NEJM Evidence

Volume 3 No. 12 December 2024

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 25 Jan 2025]

[No new digest content identified]

Pediatrics

Volume 155, Issue 1 1 January 2025

<https://publications.aap.org/pediatrics/issue/155/1>

[Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 1 January 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-1>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 25 Jan 2025)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 25 Jan 2025)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 25 Jan 2025)

Clinical and economic burden of varicella in pediatric patients hospitalized in four institutions in Guatemala

Mario Melgar, Ingrid Sajmolo, André Chocó, Lidia Ortiz, Ana Gabriela Cordova, Luis Hernández, Irwing Rivera, Ashly Zuñiga, Claudia Beltrán, Sebastian Medina, Marcel Marcano-Lozada

Research Article | published 24 Jan 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004165>

Changes and determinants of pneumococcal vaccine uptake in Ethiopia

Biniyam Tedla Mamo, Ferehiwot Gebrehiwot Geram, Kebron Yihenew Getnet, Zelalem Tazu Bongor

Research Article | published 22 Jan 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004192>

High coverage and equitable distribution of COVID-19 vaccine uptake in two vulnerable areas in Bangladesh

Muhammed Nazmul Islam, Manuela De Allegri, Emmanuel Bonnet, Malabika Sarker, Jean-Marc Goudet, Lucas Franceschin, Valéry Ridde

Research Article | published 17 Jan 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004178>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 25 Jan 2025)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 25 Jan 2025)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 25 Jan 2025]

A systematic review on malaria and Tuberculosis (TB) vaccine challenges in sub-Saharan African clinical trials

Maonezi Abas Hamisi, Nur Ain Mohd Asri, Aini Syahida Mat Yassim, Rapeah Suppian

Research Article | published 24 Jan 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0317233>

Characteristics influencing COVID-19 testing and vaccination among Spanish-speaking Latine persons in North Carolina

Sandy K. Aguilar-Palma, Thomas P. McCoy, Lilli Mann-Jackson, Jorge Alonzo, Mohammed Sheikh Eldin Jibriel, Dorcas Mabiala Johnson, Tony Locklear, Amanda E. Tanner, Mark A. Hall, Alain G. Bertoni, Ana D. Sucaldito, Laurie P. Russell, Scott D. Rhodes

Research Article | published 23 Jan 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0317794>

Protect or prevent? A practicable framework for the dilemmas of COVID-19 vaccine prioritization

Raghu Arghal, Harvey Rubin, Shirin Saeedi Bidokhti, Saswati Sarkar

Research Article | published 22 Jan 2025 PLOS ONE
<https://doi.org/10.1371/journal.pone.0316294>

[A study of association between maternal tetanus toxoid immunization and neonatal mortality in the context of Bangladesh](#)

Sujan Kumar Naha, Md. Efty Islam Arpon, Rifa Tasfia Siddique, Farjana Rahman Ripa, Mohammad Nayeem Hasan, Md. Jamal Uddin

Research Article | published 17 Jan 2025 PLOS ONE
<https://doi.org/10.1371/journal.pone.0316939>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 25 Jan 2025]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

January 28, 2025 | vol. 122 | no. 4

<https://www.pnas.org/toc/pnas/122/4>

[New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 12, December 2024

<https://academic.oup.com/pnasnexus/issue/3/12>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 4 - August 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 189 December 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/189/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

January 2025 Volume 292 Issue 2039

<https://royalsocietypublishing.org/toc/rspb/current>

Biological science practices

[More than a token photo: humanizing scientists enhances student engagement](#)

Robin A. Costello, et al.

Published: 22 January 2025 Article ID: 20240879

<https://doi.org/10.1098/rspb.2024.0879>

Public Health

Volume 237 Pages 1-466 (December 2024)
<https://www.sciencedirect.com/journal/public-health/vol/237/suppl/C>
[Reviewed earlier]

Public Health Ethics

Volume 17, Issue 3, November 2024
<http://phe.oxfordjournals.org/content/current>
[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1
<https://karger.com/phg/issue/27/1>
[Reviewed earlier]

Public Health Reports

Volume 139 Issue 6, November/December 2024
<https://journals.sagepub.com/toc/phrg/139/6>
[Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 1, January 2025
<https://journals.sagepub.com/toc/QHR/current>
[Reviewed earlier]

Research Ethics

Volume 21 Issue 1, January 2025
<http://journals.sagepub.com/toc/reab/current>
[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>
[Accessed 25 Jan 2025]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

21 Jan 2025

[**Analysis of the surveillance system for adverse events following Immunization \(AEFI\) related to COVID-19 vaccines in Colombia, 2021-2023**](#)

Original research | Spanish |

Risk Analysis

Volume 44, Issue 12 Pages: 2755-2934 December 2024
<https://onlinelibrary.wiley.com/toc/15396924/current>
Special Issue: Risk Science Foundations and COVID
[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>
[Accessed 25 Jan 2025]

Original Research

Assessing COVID-19 Pandemic-Era Vaccine Uptake and Adherence to Prevention Measures: A Comparative Analysis Among Men and Women Using Lot Quality Assurance Sampling in Central Uganda

Anguyo RO, Mukama SC, Tasaga C, Bindeeba DS, Senyimba C, Ezajobo S, Nakawesi JS, Mugisa A, Nakubulwa SK, Namitala II E, Aniku G, Katongole SP
Risk Management and Healthcare Policy 2025, 18:249-268
Published Date: 21 January 2025

Science

Volume 387| Issue 6732| 24 Jan 2025
<https://www.science.org/toc/science/current>
Editorial

Citizen of science

Alan I. Leshner, H. Holden Thorp
23 Jan 2025

Floyd Bloom, who died on 8 January, was a towering figure in both neuroscience and the scientific community as a whole. As Editor-in-Chief of *Science* from 1995 to 2000, he presided over a transformative period in which the journal embraced the digital age, expanding its reach and impact while advocating for open access and the sharing of data. His groundbreaking contributions to neuropharmacology and the understanding of neurotransmitters were only part of his legacy. Through his leadership, mentorship, and pioneering research, Bloom left an indelible mark on the scientific world, one that continues to inspire new generations...

Science and Engineering Ethics

Volume 31, Issue 1 February 2025
<https://link.springer.com/journal/11948/volumes-and-issues/31-1>

Embedded Ethics in Practice: A Toolbox for Integrating the Analysis of Ethical and Social Issues into Healthcare AI Research

Theresa Willem, Marie-Christine Fritzsche, Alena Buyx
Original Research/Scholarship Open access 24 December 2024 Article: 3

Science Translational Medicine

Volume 17| Issue 781| 15 Jan 2025
<https://www.science.org/toc/stm/current>
[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 25 Jan 2025]
[No new digest content identified]

Social Science & Medicine

Volume 364 January 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/364/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 25 Jan 2025]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 6 December 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-6>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 63 January–February 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/63/suppl/C>

Review article Open access

[Vaccinations for Hajj: Enhancing health and global health security](#)

Anas A. Khan, Bander S. Balkhi, Fahad A. Alamri, Ghadah S. Alsaleh, ... Hani Jokhdar

Article 102784

Abstract

The Hajj pilgrimage, one of the world's largest and most diverse mass gatherings, poses unique challenges for preventing infectious disease outbreaks. Vaccinations are vital in reducing the risk and spread of diseases during this event. This narrative review examines the impact of vaccination programs on infectious disease mitigation during the Hajj and their broader implications for global health security (GHS). Mandatory vaccination protocols against Meningococcal Meningitis, Yellow Fever, Influenza, pneumococcal diseases, and COVID-19 have demonstrated significant success in controlling infection spread during Hajj. Furthermore, the integration of digital health passports or similar technologies offers the potential to enhance surveillance, streamline vaccination verification, and further minimize risks associated with mass gatherings. This study demonstrates the critical role of vaccination programs in protecting pilgrims. It also explores how technologies can be used to monitor pilgrim health status, enabling rapid identification and mitigation of potential outbreaks, thus contributing to GHS.

Book review Open access

[Routledge Handbook of Infectious Diseases – A Geographical Guide, 3rd edition, Eskild Petersen, Lin H. Chen, Patricia Schlagenhauf \(Eds.\) \(2025\)](#)

Gerard T. Flaherty

Article 102788

Tropical Medicine & International Health

Volume 30, Issue 1 Pages: i-iv, 1-69 January 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

OPINION

[Mpox as an emerging health threat for survivors of sex trafficking](#)

Olabode Ekerin, Deborah Oluwaseun Shomuyiwa, Isaac Olushola Ogunkola, Yusuff Adebayo Adebisi, Emery Manirambona

Pages: 1-3

First Published: 01 December 2024

SYSTEMATIC REVIEW

EDITORS' CHOICE

[HBV, HCV and HIV among inmates in Latin America and the Caribbean: A systematic review and meta-analysis](#)

Mariana Cavaleiro Magri, Caroline Manchiero, Bianca Peixoto Dantas, Wanderley Marques Bernardo, Edson Abdala, Fátima Mitiko Tengan

Pages: 4-13

First Published: 13 December 2024

Vaccine

Volume 46 6 February 2025

<https://www.sciencedirect.com/journal/vaccine/vol/46/suppl/C>

Editorial No access

[Quantum vaccinology: A new science and epistemological abstraction framework for developing new vaccines and understanding the generation of the immune response](#)

Gregory A. Poland, José de la Fuente

Article 126641

Discussion No access

[Intravenous vaccination with BCG against tuberculosis: Strengths and questions deserving further research](#)

Mario Alberto Flores-Valdez

Article 126666

Discussion No access

[Influenza vaccination for children in Europe: The health of every child matters](#)

Helena C. Maltezos, Gregory A. Poland, Raul Ortiz de Lejarazu

Article 126675

Review article Open access

[Systematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines](#)

Jeong-Yeon Cho, Haeseon Lee, Warisa Wannadisai, Jeffrey Vietri, Nathorn Chaiyakunapruk

Article 126656

Review article Open access

[Meeting summary: Global vaccine and immunization research forum, 2023](#)

Birgitte Giersing, Annie X. Mo, Angela Hwang, Shahida Baqar, ... B. Fenton Hall

Article 126686

Research article Open access

[Missed vaccines in pregnant women: A contributing factor to pertussis outbreak in newborns and infants](#)

Research article Abstract only

Undernutrition and antibody response to measles, tetanus and Haemophilus Influenzae type b (Hib) vaccination in pre-school south African children: The VHEMBE birth cohort study

Brenda Eskenazi, Stephen Rauch, Basant Elsiwi, Riana Bornman, ... Jonathan Chevrier

Article 126564

Highlights

- Infectious diseases are a major source of childhood morbidity/mortality worldwide.
- Undernutrition may affect the immune response to certain vaccines.
- The VHEMBE study examined relationships between undernutrition and antibody levels.
- Undernourished vaccinated children had lower measles antibody levels at 3.5/5 years.
- Undernutrition was associated with lower tetanus antibodies in girls but not boys

Abstract

Background

Under-vaccination is undoubtedly driving recent worldwide measles outbreaks, but undernutrition may also be playing a role in low- and middle-income countries. Studies have shown reduced immune response to vaccines in undernourished children but few have followed children beyond infancy, when they are more likely to be exposed to infectious diseases.

Methods

In the Venda Health Examination of Mothers, Babies and the Environment (VHEMBE) South African birth cohort study, we examined the relationship between undernutrition, as measured by stunting and other growth measures, and vaccine-specific serum antibody level to three different vaccine types: measles, tetanus and Haemophilus influenzae type b (Hib). We included 621 fully-vaccinated children with anthropometric measurements at ages 1, 2, and 3.5 years and antibody levels at 3.5 and 5 years.

Results

At 5 years of age, 90.4% of fully-vaccinated children were protected against measles, 66.7% against tetanus, and 56.1% against Hib. Children who were stunted or had any indicator of diminished growth at 3.5 years averaged a 24.1% (95% CI = -44.2, 0.6) or a 27.2% (95% CI = -45.1, -1.3) lower antibody titer for measles, respectively, relative to those with normal growth. In addition, girls, but not boys, with any indicator of diminished growth at 3.5 years averaged a 36.8% (-59.3, -7.0) lower antibody titer for tetanus. We found no association between undernutrition and Hib antibody titers.

Conclusions

Early life undernutrition may be associated with lower induction or persistence of antibody responses to certain vaccines. Addressing child undernutrition may improve vaccine efficacy and reduce the burden of vaccine-preventable diseases.

Research article Open access

Exploring the ethics of using fictional stories for health education on social media to share information and emotions about the HPV vaccine: A cross-sectional study with interdisciplinary health experts

Philip M. Massey, Regan M. Murray, Kelli Kostizak, Wen-Juo Lo, Michael Yudell

Article 126575

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 25 Jan 2025]

Open Access Communication

Zero-Dose Vaccination of Self-Paid Vaccines Among Migrant and Left-Behind Children in China: Evidence from Zhejiang and Henan Provinces

by Yaguan Zhou, Heng (Anna) Du, Shu Chen, Shenglan Tang and Xiaolin Xu

Vaccines 2025, 13(2), 118; <https://doi.org/10.3390/vaccines13020118> - 24 Jan 2025

Abstract

Background/Objectives: As zero-dose vaccination has become a global health concern, understanding the practice of self-paid immunizations in migrant and left-behind children in China is crucial to the prevention and control of infectious diseases. Methods: A cross-sectional study was conducted in 1648

Value in Health

January 2025 Volume 28 Issue 1 p1-174

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 185 January 2025

<https://www.sciencedirect.com/journal/world-development/vol/184/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 25 Jan 2025]

[Filters: *Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

arXiv:2501.13802 [pdf, html, other]

Enhancing LLMs for Governance with Human Oversight: Evaluating and Aligning LLMs on Expert Classification of Climate Misinformation for Detecting False or Misleading Claims about Climate Change

Mowafak Allaham, Ayse D. Lokmanoglu, Sol P. Hart, Erik C. Nisbet

Climate misinformation is a problem that has the potential to be substantially aggravated by the development of Large Language Models (LLMs). In this study we evaluate the potential for LLMs to be part of the solution for mitigating online dis/misinformation rather than the problem. Employing a public expert annotated dataset and a curated sample of social media content we evaluate the performance of proprietary vs. open source LLMs on climate misinformation classification task, comparing them to existing climate-focused computer-assisted tools and expert assessments. Results

show (1) state-of-the-art (SOTA) open-source models substantially under-perform in classifying climate misinformation compared to proprietary models, (2) existing climate-focused computer-assisted tools leveraging expert-annotated datasets continues to outperform many of proprietary models, including GPT-4o, and (3) demonstrate the efficacy and generalizability of fine-tuning GPT-3.5-turbo on expert annotated dataset in classifying claims about climate change at the equivalency of climate change experts with over 20 years of experience in climate communication. These findings highlight 1) the importance of incorporating human-oversight, such as incorporating expert-annotated datasets in training LLMs, for governance tasks that require subject-matter expertise like classifying climate misinformation, and 2) the potential for LLMs in facilitating civil society organizations to engage in various governance tasks such as classifying false or misleading claims in domains beyond climate change such as politics and health science.

[arXiv:2501.11705](#) [[pdf](#), [other](#)]

[Human services organizations and the responsible integration of AI: Considering ethics and contextualizing risk\(s\)](#)

[Brian E. Perron](#), [Lauri Goldkind](#), [Zia Qi](#), [Bryan G. Victor](#)

This paper examines the responsible integration of artificial intelligence (AI) in human services organizations (HSOs), proposing a nuanced framework for evaluating AI applications across multiple dimensions of risk. The authors argue that ethical concerns about AI deployment -- including professional judgment displacement, environmental impact, model bias, and data laborer exploitation -- vary significantly based on implementation context and specific use cases. They challenge the binary view of AI adoption, demonstrating how different applications present varying levels of risk that can often be effectively managed through careful implementation strategies. The paper highlights promising solutions, such as local large language models, that can facilitate responsible AI integration while addressing common ethical concerns. The authors propose a dimensional risk assessment approach that considers factors like data sensitivity, professional oversight requirements, and potential impact on client wellbeing. They conclude by outlining a path forward that emphasizes empirical evaluation, starting with lower-risk applications and building evidence-based understanding through careful experimentation. This approach enables organizations to maintain high ethical standards while thoughtfully exploring how AI might enhance their capacity to serve clients and communities effectively.

[arXiv:2501.10383](#) [[pdf](#), [html](#), [other](#)]

[The Generative AI Ethics Playbook](#)

[Jessie J. Smith](#), [Wesley Hanwen Deng](#), [William H. Smith](#), [Maarten Sap](#), [Nicole DeCario](#), [Jesse Dodge](#)

The Generative AI Ethics Playbook provides guidance for identifying and mitigating risks of machine learning systems across various domains, including natural language processing, computer vision, and generative AI. This playbook aims to assist practitioners in diagnosing potential harms that may arise during the design, development, and deployment of datasets and models. It offers concrete strategies and resources for mitigating these risks, to help minimize negative impacts on users and society.

Drawing on current best practices in both research and ethical considerations, this playbook aims to serve as a comprehensive resource for AI/ML practitioners. The intended audience of this playbook includes machine learning researchers, engineers, and practitioners who are involved in the creation and implementation of generative and multimodal models (e.g., text-to-text, image-to-image, text-to-image, text-to-video).

Specifically, we provide transparency/documentation checklists, topics of interest, common questions, examples of harms through case studies, and resources and strategies to mitigate harms throughout the Generative AI lifecycle. This playbook was made collaboratively over the course of 16 months through extensive literature review of over 100 resources and peer-reviewed articles, as well as through an initial group brainstorming session with 18 interdisciplinary AI ethics experts from industry and academia, and with additional feedback from 8 experts (5 of whom were in the initial brainstorming session).

We note that while this playbook provides examples, discussion, and harm mitigation strategies, research in this area is ongoing. Our playbook aims to be a practically useful survey, taking a high-level view rather than aiming for covering the entire existing body of research.

[arXiv:2501.12395](https://arxiv.org/abs/2501.12395) (cross-list from q-bio.QM) [[pdf](#), [other](#)]

[Predicting high dengue incidence in municipalities of Brazil using path signatures](#)

[Daniel A.M. Villela](#)

Predicting whether to expect a high incidence of infectious diseases is critical for health surveillance. In the epidemiology of dengue, environmental conditions can significantly impact the transmission of the virus. Utilizing epidemiological indicators alongside environmental variables can enhance predictions of dengue incidence risk. This study analyzed a dataset of weekly case numbers, temperature, and humidity across Brazilian municipalities to forecast the risk of high dengue incidence using data from 2014 to 2023. The framework involved constructing path signatures and applying lasso regression for binary outcomes. Sensitivity reached 75%, while specificity was extremely high, ranging from 75% to 100%. The best performance was observed with information gathered after 35 weeks of observations using data augmentation via embedding techniques. The use of path signatures effectively captures the stream of information given by epidemiological and climate variables that influence dengue transmission. This framework could be instrumental in optimizing resources to predict high dengue risk in municipalities in Brazil and other countries after learning these country patterns.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 25 Jan 2025]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 25 Jan 2025]

[Filter: All articles]

[Co-coverage of social protection programs and maternal and child nutrition interventions in Bangladesh, India and Nepal](#)

Samuel Scott, Sumanta Neupane, Hana Tasic, Nadia Akseer, Sunny Kim, Harold Alderman, Bianca Carducci, Rebecca Heidkamp

medRxiv 2025.01.22.25320966; doi: <https://doi.org/10.1101/2025.01.22.25320966>

Abstract

Social protection programs (SPPs) are common in South Asia, a global malnutrition hotspot. Provision of SPP benefits as well as essential health/nutrition interventions to mothers and children are goals for optimal health and development outcomes, but the degree of co-coverage of SPPs and health/nutrition interventions among beneficiary households is poorly described. Using six population-based surveys from 2012 to 2019 in Bangladesh, India, and Nepal (n=253,703 women with children under five years of age), we examined data availability for SPPs (food and cash transfers) and health/nutrition interventions, and estimated their coverage and co-coverage during the last pregnancy (interventions: take-home food rations plus at least four antenatal care visits, receipt of at least 100 iron-folic acid tablets, deworming, and tetanus injections), after delivery (cash benefit plus the interventions above), and in children (take-home ration for the child plus vitamin A supplementation, deworming, iron syrup, growth monitoring, and nutrition counseling). In India, 52% and 51% of women and children, respectively, received food transfers, but only 3% and 8% received food plus all health/nutrition interventions. In India and Nepal, respectively, cash after delivery was received by 41% and 86% of women, but only 2% and 21% received cash after delivery plus all health/nutrition interventions. There was insufficient data to estimate coverage of both SPPs and health/nutrition interventions in

Bangladesh. Our findings highlight the need for data on both SPP and health/nutrition intervention coverage in household surveys. There are missed opportunities to reach women and children with interventions across multiple sectors.

Development and application of Pandemic Projection Measures (PPM) for forecasting the COVID-19 outbreak

Shu-Ren Chang

medRxiv 2020.05.30.20118158; doi: <https://doi.org/10.1101/2020.05.30.20118158> Revision

Abstract

This study aims to provide an accessible and dynamic estimate method to project the Covid-19 trend and hopefully it will help inform policymakers to allocate the needed medical equipment and supplies for saving more lives. A set of newly developed Pandemic Projection Measures (PPM) had been successfully applied to project daily new cases across countries. During the development, numerous trial and error iterations had been performed and then improved with live data. The procedures and computations for the PPM including Uphill Index (UHI), Downhill Indices (DHI), and Error Band Projection (EBP) estimates were explained and discussed along with graphical projections. The PPM was computed with daily live data for the USA, four U.S. states (Illinois, Massachusetts, New Jersey, and New York), France, Italy, Spain, Germany, and China. The results indicated that with the PPM estimations, the daily projections for the future trend were robust to reflect the most plausibility, since the PPM can be updated frequently...

Integrating Macroeconomic and Public Health Impacts in Social Planning Policies for Pandemic Response

Ofer Cornfeld, Kaicheng Niu, Oded Neeman, Michael Roswell, Gabi Steinbach, Stephen J. Beckett, Yorai Wardi, Joshua S. Weitz, Eran Yashiv

medRxiv 2025.01.21.25320900; doi: <https://doi.org/10.1101/2025.01.21.25320900>

A Scoping Review of Artificial Intelligence Applications in Clinical Trial Risk Assessment

Douglas Teodoro, Nona Naderi, Anthony Yazdani, Boya Zhang, Alban Bornet

medRxiv 2025.01.21.25320310; doi: <https://doi.org/10.1101/2025.01.21.25320310>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints] Selected Research

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 25 Jan 2025]

Study Protocol Open Access

A pilot protocol for surveillance of infection and antibiotic prescribing in primary healthcare across the globe: Antibiotic Prescribing in Primary Healthcare Point Prevalence Survey (APC-PPS)

[version 1; peer review: awaiting peer review]

Aislinn Cook, et al.

Abstract

Little data is available from the primary healthcare setting in low- and middle-income countries to describe the burden of clinical infections and antibiotic prescribing proportions for those infections. The AWaRe Antibiotic Book provides a framework for assessing antibiotic prescribing in primary healthcare

but requires understanding both frequency of clinical infections and their antibiotic prescribing proportions. The Antibiotic Prescribing in Primary Healthcare Point Prevalence Survey (APC-PPS) project is a series of point prevalence surveys conducted at primary healthcare facilities in LMICs to capture the frequency of consultation for different clinical infections and diagnoses and the frequency and type of antibiotic prescribing associated with these infections in primary healthcare facilities...

* * * *

Think Tanks

Brookings [to 25 Jan 2025]

<http://www.brookings.edu/>

Reports, Events

Research

Tracking regulatory changes in the second Trump administration

January 22, 2025

The Brookings Center on Regulation and Markets Regulatory Tracker ("Reg Tracker") provides background information and status updates on a curated selection of significant regulatory and deregulatory changes made by the Trump administration. This tracker allows you to monitor a curated selection of new, delayed, and repealed rules, notable guidance and policy revocations, executive actions, and important court battles across key policy areas such as environmental, health, labor, and more.

Center for Global Development [to 25 Jan 2025]

<https://www.cgdev.org/>

All Research

No new digest content identified.

Chatham House [to 25 Jan 2025]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 25 Jan 2025]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 25 Jan 2025]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 25 Jan 2025]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 25 Jan 2025]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 25 Jan 2025]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 25 Jan 2025]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 25 Jan 2025]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Research Jan 21, 2025

Parental Factors Associated With Measles-Mumps-Rubella Vaccination in US Children Younger Than 5 Years

Study that determines the association between parental characteristics and MMR measles-mumps-rubella vaccination status of children in the United States.

Urban Institute [to 25 Jan 2025]

<https://www.urban.org/publications>

New Research Publications - Selected

World Economic Forum [to 25 Jan 2025]

<https://agenda.weforum.org/press/>

Media [Selected]

Annual Meeting 2025: Collaboration for the Intelligent Age

News 24 Jan 2025

- At a crucial moment for the world economy, the World Economic Forum's Annual Meeting 2025 served as a platform for advancing dialogue, cooperation and partnerships.
- Close to 3,000 leaders from government, business, civil society and academia from more than 130 countries, including over 350 heads of state and government and ministers, participated in the meeting around the theme of "Collaboration for the Intelligent Age".
- With the geopolitical and geoeconomic landscapes undergoing a paradigm shift, the meeting explored how to unlock the benefit of new technologies responsibly, strengthen social and economic resilience, safeguard the planet, and advance regional and global security.
- Revisit sessions from the Annual Meeting [here](#) and on social media using #WEF25. Watch the [Highlights Film here](#).

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *